A landscape of driver mutations in melanoma

Cited by (1,006)

Items 401–500 of 1,006

1. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
   Chengqian Yin, Bo Zhu, Ting Zhang, Tongzheng Liu, Shuyang Chen, Yu Liu, Xin Li, Xiao Miao, Shanshan Li, Xia Mi et al. · 2019 · Cell
2. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
   Alessandro Rossi, Michela Roberto, Martina Panebianco, Andrea Botticelli, Federica Mazzuca, Paolo Marchetti · 2019 · European Journal of Pharmacology
3. Neurofibromin and suppression of tumorigenesis: beyond the GAP
   Juan Mo, Stefanie L. Moye, Renee M. McKay, L. Le · 2022 · Oncogene
4. Alternative RNA splicing and cancer
   Sali Liu, Chonghui Cheng · 2013 · Wiley Interdisciplinary Reviews - RNA
5. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma
   Andrew S. McNeal, Kevin Liu, Vihang Nakhate, Christopher A. Natale, Elizabeth K. Duperret, Brian C. Capell, Tzvete Dentchev, Shelley L. Berger, Meenhard Herlyn, John T. Seykora et al. · 2015 · Cancer Discovery
6. Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression
   Petko P. Fiziev, Kadir Caner Akdemir, John P. Miller, Emily Zhi-Yun Keung, Neha S. Samant, Sneha Sharma, Christopher A. Natale, Christopher J. Terranova, Mayinuer Maitituoheti, Samirkumar B. Amin et al. · 2017 · Cell Reports
7. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
   Joseph David Khoury, Wei‐Lien Wang, Victor Gerardo Prieto, Leonard Jeffrey Medeiros, Neda Kalhor, Meera Hameed, Russell R. Broaddus, Stanley R. Hamilton · 2017 · Clinical Cancer Research
8. DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers
   David Mas-Ponte, Fran Supek · 2020 · Nature Genetics
9. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
   Hyo Song Kim, Minkyu Jung, Hari Kang, Hye Ryun Kim, C. W. Park, S-M Kim, Sang Joon Shin, Se Hoon Kim, S G Kim, Eun‐Kyung Kim et al. · 2017 · Oncogene
10. INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma
    Bingying Zhou, Li Wang, Shu Zhang, Brian D. Bennett, Fan He, Yan Zhang, Chengliang Xiong, Leng Han, Lixia Diao, Pishun Li et al. · 2016 · Genes & Development
11. Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
    Antonia L. Pritchard, Nicholas K. Hayward · 2013 · Clinical Cancer Research
12. HSP90: Enabler of Cancer Adaptation
    Alex M. Jaeger, Luke J. Whitesell · 2018 · Annual Review of Cancer Biology
13. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
    Da Meng, Richard D. Carvajal · 2019 · American Journal of Clinical Dermatology
14. Interpretable deep learning uncovers cellular properties in label-free live cell images that are predictive of highly metastatic melanoma
    Assaf Zaritsky, Andrew Raymond Jamieson, Erik S. Welf, Andres J. Nevarez, Justin Cillay, Uğur Eskiocak, Brandi L. Cantarel, Gaudenz M. Danuser · 2021 · Cell Systems
15. Targeting PAK1
    Galina Semenova, Jonathan Chernoff · 2017 · Biochemical Society Transactions
16. Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm
    Michelle L. Turski, Smruti J. Vidwans, Filip Jankú, Ignacio Garrido‐Laguna, Javier Munoz, Richard B. Schwab, Vivek Subbiah, Jordi Ahnert Rodon, Razelle Kurzrock · 2016 · Molecular Cancer Therapeutics
17. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma
    Inger Z. M. Kreuger, Roderick C. Slieker, Tim van Groningen, Remco van Doorn · 2022 · Journal of Investigative Dermatology
18. SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation
    Catherine C. Fahey, Ian J. Davis · 2017 · Cold Spring Harbor Perspectives in Medicine
19. EZH2 as a potential target in cancer therapy
    Michael T. McCabe, Caretha L. Creasy · 2014 · Epigenomics
20. Autophagy in UV Damage Response
    Ashley Sample, Yu‐Ying He · 2016 · Photochemistry and Photobiology
21. Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
    X Chan, Alamdeep Singh, Narin Osman, Terrence J. Piva · 2017 · International Journal of Molecular Sciences
22. Cortical branched actin determines cell cycle progression
    Nicolas Molinié, Svetlana N. Rubtsova, Artem I. Fokin, Sai Prasanna Visweshwaran, Nathalie Rocques, Anna Polesskaya, Anne Schnitzler, Sophie Vacher, Evgeny V. Denisov, Л. А. Таширева et al. · 2019 · Cell Research
23. Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update
    Leigh A. Compton, George F. Murphy, Christine Guo Lian · 2015 · Dermatopathology
24. FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm
    Iraz T. Aydin, Rachel Melamed, Sarah J. Adams, Mireia Castillo-Martín, Ahu Demir, Diana Bryk, Georg Brunner, Carlos Cordon‐Cardo, Iman Osman, Raúl Rabadán et al. · 2014 · JNCI Journal of the National Cancer Institute
25. A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers
    Hengrui Liu, James P. Dilger, Jun Lin · 2022 · Pharmacology & Therapeutics
26. HLA ligandome tumor antigen discovery for personalized vaccine approach
    Hans‐Georg Rammensee, Harpreet Singh‐Jasuja · 2013 · Expert Review of Vaccines
27. RHO GTPases in cancer: known facts, open questions, and therapeutic challenges
    Xosé R. Bustelo · 2018 · Biochemical Society Transactions
28. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
    Rajesh R. Singh, Keyur Pravinchandra Patel, Mark J. Routbort, Kenneth Aldape, Xinyan Y. Lu, Jawad Manekia, R Abraham, Neelima G. Reddy, Bedia A. Barkoh, Jincy Veliyathu et al. · 2014 · British Journal of Cancer
29. Rapid learning for precision oncology
    Jeff Shrager, Jay Martin Tenenbaum · 2014 · Nature Reviews Clinical Oncology
30. Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
    Ileabett M. Echevarría-Vargas, Patricia I. Reyes-Uribe, Adam N. Guterres, Xiangfan Yin, Andrew V. Kossenkov, Qin Liu, Gao Zhang, Clemens Krepler, Chaoran Cheng, Zhi Wei et al. · 2018 · EMBO Molecular Medicine
31. Phytochemicals for the Management of Melanoma
    Harish Chandra Pal, Katherine Marchiony Hunt, Ariana C. Diamond, Craig A. Elmets, Farrukh Afaq · 2016 · Mini-Reviews in Medicinal Chemistry
32. The genetics of melanoma: recent advances
    Hill, Victoria K., Gartner, Jared J., Samuels, Yardena, Goldstein, Alisa M. · 2013 · Annual Review of Genomics and Human Genetics
33. Genetics of melanoma progression: the rise and fall of cell senescence
    Dorothy C. Bennett · 2015 · Pigment Cell & Melanoma Research
34. miR-339-3p Is a Tumor Suppressor in Melanoma
    Claudia E.M. Weber, Chonglin Luo, Agnes Hotz‐Wagenblatt, Adriane Gardyan, Theresa Kordaß, Tim Holland‐Letz, Wolfram Osen, Stefan B. Eichmüller · 2016 · Cancer Research
35. Malignant melanoma: diagnosis, treatment and cancer stem cells
    Zuzana Kozovská, Veronika Gabrisova, Lucia Kučerová · 2016 · Neoplasma
36. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
    Che‐Hung Shen, Sun Hye Kim, Sebastian Trousil, Dennie Tompers Frederick, Adriano Piris, Ping Yuan, Li Cai, Lei Gu, Man Li, Jung Hyun Lee et al. · 2016 · Nature Medicine
37. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
    Ioana Cosgarea, Selma Ugurel, Antje Sucker, Elisabeth Livingstone, Lisa Zimmer, Mirjana Ziemer, Jochen Sven Utikal, Peter Mohr, Christiane Pfeiffer, Claudia Pföhler et al. · 2017 · Oncotarget
38. A slow-cycling subpopulation of melanoma cells with highly invasive properties
    Michela Perego, M Maurer, Justina Wang, Sydney M. Shaffer, André C. Müller, Katja Parapatics, L Li, Denitsa M. Hristova, Sally A. Shin, Frederick Keeney et al. · 2017 · Oncogene
39. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
    Susanne Horn, Sonia Leonardelli, Antje Sucker, Dirk Schadendorf, Klaus Griewank, Annette Paschen · 2017 · JNCI Journal of the National Cancer Institute
40. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
    Lokeswari Prathyusha Tangella, Michael E. Clark, Elin Solomonovna Gray · 2020 · Biochimica et Biophysica Acta (BBA) - General Subjects
41. P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma
    Christy C. Ong, Adrian M. Jubb, Diana Jakubiak, Wei Zhou, Joachim Rudolph, Peter M. Haverty, Marcin Kowanetz, Yibing Yan, Jarrod R. Tremayne, Richard Lisle et al. · 2013 · JNCI Journal of the National Cancer Institute
42. Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down syndrome and mouse models
    Maite Mendióroz, Catherine Do, Xiaoling Jiang, Chunhong Liu, Huferesh K. Darbary, Charles F. Lang, J. P. Lin, Anna C. Thomas, Sayeda Nasreen Abu-Amero, Philip Stanier et al. · 2015 · Genome biology
43. Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers
    Campbell D. Lawson, Cheng Fan, Natalia Mitin, Nicole M. Baker, Samuel D. George, David M. Graham, Charles M. Perou, Keith Burridge, Channing J. Der, Kent L. Rossman · 2016 · Cancer Research
44. Carcinogen susceptibility is regulated by genome architecture and predicts cancer mutagenesis
    Pablo E. García-Nieto, Erin K. Schwartz, Devin A. King, Jonas Paulsen, Philippe Collas, Rafael E. Herrera, Ashby J. Morrison · 2017 · The EMBO Journal
45. RETRACTED: PKA-Mediated Phosphorylation of ATR Promotes Recruitment of XPA to UV-Induced DNA Damage
    Jarrett, Stuart G., Horrell, Erin M. Wolf, Christian, Perry A., Vanover, Jillian C., Boulanger, Mary C., Zou, Yue, D’Orazio, John A. · 2014 · Molecular Cell · Retracted
46. Oncogenic RIT1 mutations in lung adenocarcinoma
    Berger Ah, Marcin B. Imielinski, Fujiko F. Duke, Jeremiah A. Wala, Nathan O. Kaplan, Shi Gx, Douglas Andres, Matthew M. Meyerson · 2014 · Oncogene
47. Pathology of Melanotic Schwannoma
    Borislav A. Alexiev, Pauline M. Chou, Lawrence J. Jennings · 2018 · Archives of Pathology & Laboratory Medicine
48. Adaptive redox homeostasis in cutaneous melanoma
    Liaisan R. Arslanbaeva, Massimo Mattia Santoro · 2020 · Redox Biology
49. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
    Geniver El Tekle, Tiziano Bernasocchi, Arun M. Unni, Francesco Bertoni, Davide Rossi, Mark A. Rubin, Jean-Philippe Paul. Theurillat · 2021 · Trends in cancer
50. Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance
    William Wagstaff, Rimel N. Mwamba, Karina Grullon, Mikhayla L. Armstrong, Piao Zhao, Bryce K Hendren-Santiago, Kevin H. Qin, Alexander J. Li, Daniel A. Hu, Andrew Youssef et al. · 2022 · Genes & Diseases
51. Molecular analysis of diffuse intrinsic brainstem gliomas in adults
    Germán Reyes-Botero, Marine Giry, Karima Mokhtari, Marianne Labussière, Ahmed Idbaïh, Jean‐Yves Delattre, Florence Laigle–Donadey, Marc Sanson · 2013 · Journal of Neuro-Oncology
52. Clonal Architectures and Driver Mutations in Metastatic Melanomas
    Li Ding, Minjung Kim, Krishna Kanchi, Nathan D. Dees, Charles Lu, Malachi Griffith, David Fenstermacher, Hyeran Sung, Christopher A. Miller, Brian D. Goetz et al. · 2014 · PLoS ONE
53. Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines
    Georgina Alexandra Cardama, Maria Julieta Comin, Leandro Hornos, Nazareno González, Lucas A. Defelipe, Adrian Gustavo Turjanski, Daniel F. Alonso, Daniel Eduardo Gomez, Pablo Lorenzano Menna · 2013 · Anti-Cancer Agents in Medicinal Chemistry
54. Metastatic melanoma treatment: Combining old and new therapies
    Ryan J. Davey, André van der Westhuizen, Nikola A. Bowden · 2015 · Critical Reviews in Oncology/Hematology
55. Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations
    Carlos L. Araya, Can Cenik, Jason Reuter, Gert Kiss, Vijay S. Pande, Michael P. Snyder, William James Greenleaf · 2015 · Nature Genetics
56. Melanoma antigens and related immunological markers
    Jacob Pitcovski, Ehud Shahar, Elina Aizenshtein, Raphael Gorodetsky · 2017 · Critical Reviews in Oncology/Hematology
57. The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
    Restivo, Gaetana, Diener, Johanna, Cheng, Phil F., Kiowski, Gregor, Bonalli, Mario, Biedermann, Thomas, Reichmann, Ernst, Levesque, Mitchell P., Dummer, Reinhard, Sommer, Lukas · 2017 · Nature Communications
58. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
    Anja Heinemann, Carleen M. Cullinane, Ricardo De Paoli‐Iseppi, James S. Wilmott, Dilini Gunatilake, Jason Madore, Dario Strbenac, Jean Yee Hwa Yang, Kavitha Gowrishankar, Jessamy C. Tiffen et al. · 2015 · Oncotarget
59. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
    Bradley Garman, Ioannis N. Anastopoulos, Clemens Krepler, Patricia A. Brafford, Katrin Sproesser, Yuchao Jiang, Bradley Stephen Wubbenhorst, Ravi K. Amaravadi, Joseph Bennett, Marilda Beqiri et al. · 2017 · Cell Reports
60. A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
    Gabriele Romano, Pei-Ling Chen, Ping Song, Jennifer Leigh McQuade, Roger J. Liang, Mingguang Liu, Whijae Roh, Dzifa Y. Duose, Fernando C. L. Carapeto, ­Jun Li­ et al. · 2018 · Cancer Discovery
61. The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma
    Bengt Phung, Maciej Cieśla, Adriana M. Sanna, Nicola Guzzi, Giulia Beneventi, Phuong Cao Thi Ngoc, Martin Lauss, Rita Cabrita, Eugenia Cordero, Ana Bosch et al. · 2019 · Cell Reports
62. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
    Yanni Ma, Ronghui Xia, Xuhui Ma, Robert L. Judson‐Torres, Hanlin Zeng · 2021 · Frontiers in Oncology
63. The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
    Christina Jessen, Julia Katharina Charlotte Kreß, Apoorva Baluapuri, Anita Hufnagel, Werner Schmitz, Susanne Kneitz, Sabine Roth, André Marquardt, Silke Appenzeller, Carsten Patrick Ade et al. · 2020 · Oncogene
64. Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management
    Laura Maria Gosman, Dana Antonia Țăpoi, Mariana Costache · 2023 · International Journal of Molecular Sciences
65. NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
    Philipp Tschandl, Anna Sophie Berghoff, Matthias Preusser, Sebastian Burgstaller-Muehlbacher, Hubert Pehamberger, Ichiro Okamoto, Harald Kittler · 2013 · PLoS ONE
66. Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma
    Jordan Wengrod, Ding Wang, Sarah Ann Weiss, Judy Zhong, Iman Osman, Lawrence B. Gardner · 2015 · Science Signaling
67. Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs
    Eun Jung Lee, Ji Young Kim, Sang Ho Oh · 2016 · Scientific Reports
68. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
    Marieke I.G. Raaijmakers, Daniel S. Widmer, Apurva Narechania, Ossia M. Eichhoff, Sandra Nicole Freiberger, Judith Wenzina, Phil Fang Cheng, Daniela Mihic‐Probst, Rob DeSalle, Reinhard Dummer et al. · 2016 · Oncotarget
69. ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo
    Paola De Cicco, Elisabetta Panza, Giuseppe Ercolano, Chiara Armogida, Giuseppe Sessa, Giuseppe Pirozzi, Giuseppe Cirino, John Lawrence Wallace, Angela Ianaro · 2016 · Pharmacological Research
70. Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors
    Ayse Selen Yilmaz, Hatice Gülçin Özer, Jessica L. Gillespie, Dawn C. Allain, Madison N. Bernhardt, Karina Colossi Furlan, Leticia T. F. Castro, Sara B. Peters, Priyadharsini Nagarajan, Stephen Y. Kang et al. · 2016 · Cancer
71. Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
    Maria Libera Ascierto, Alvin P. Makohon-Moore, Evan J. Lipson, Janis Marie Taube, Tracee L. McMiller, Alan E. Berger, Jinshui Fan, Genevieve J. Kaunitz, Tricia R. Cottrell, Zachary A. Kohutek et al. · 2017 · Clinical Cancer Research
72. Recent Advances of Sustainable UV Shielding Materials: Mechanisms and Applications
    Ke Dai, Shuai Cao, Jiewei Yuan, Zhiwei Wang, Hong Li, Chengqian Yuan, Xuehai Yan, Ruirui Xing · 2025 · ACS Applied Materials & Interfaces
73. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
    Anna A. Marusiak, Zoe C. Edwards, Willy Hugo, Eleanor W. Trotter, María Romina Girotti, Natalie L. Stephenson, Xiangju Kong, Michael G. Gartside, Shameem Fawdar, Andrew Hudson et al. · 2014 · Nature Communications
74. Structures reveal a key mechanism of WAVE regulatory complex activation by Rac1 GTPase
    Ding, Bojian, Yang, Sheng, Schaks, Matthias, Liu, Yijun, Brown, Abbigale J., Rottner, Klemens, Chowdhury, Saikat, Chen, Baoyu · 2022 · Nature Communications
75. The potential role of hydrogen sulfide in cancer cell apoptosis
    Wei Gao, Yafang Liu, Yan-Xia Zhang, Yan Wang, Yuqing Jin, Hang Yuan, Xiaoyi Liang, Xin‐Ying Ji, Qiying Jiang, Dongdong Wu · 2024 · Cell Death Discovery
76. Canonical correlation analysis for RNA-seq co-expression networks
    Shengjun Hong, Xiangning Chen, Jin Li, Momiao Xiong · 2013 · Nucleic Acids Research
77. Revisiting determinants of prognosis in cutaneous melanoma
    Sarah Ann Weiss, Douglas Hanniford, Eva Hernando, Iman Osman · 2015 · Cancer
78. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system
    Johannes A.P. van de Nes, Marco Gessi, Antje Sucker, Inga Möller, Mathias Stiller, Susanne Horn, Simone L. Scholz, Carina Pischler, Nadine Stadtler, Bastian Schilling et al. · 2016 · Journal of Neuro-Oncology
79. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer
    Tze‐Kiong Er, Yu-Fa Su, Chun‐Chieh Wu, Chih-Chieh Chen, Jing Wang, Tsung‐Hua Hsieh, Marta Herreros‐Villanueva, Wan‐Tzu Chen, Yi‐Ting Chen, Ta‐Chih Liu et al. · 2016 · Journal of Molecular Medicine
80. Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
    Pizzimenti, Stefania, Ribero, Simone, Cucci, Marie Angele, Grattarola, Margherita, Monge, Chiara, Dianzani, Chiara, Barrera, Giuseppina, Muzio, Giuliana · 2021 · Antioxidants
81. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion
    Sarah M. Mense, Douglas Barrows, Cindy Hodakoski, Nicole Steinbach, David A. Schoenfeld, William Su, Benjamin David Hopkins, Tao Su, Barry M. Fine, Hanina H. Hibshoosh et al. · 2015 · Science Signaling
82. Identification of recurrent mutational events in anorectal melanoma
    Hui Min Yang, Susan Jean Hsiao, David F. Schaeffer, Chi K. Lai, Helen Elaine Remotti, David A. Horst, MAHESH M. MANSUKHANI, Basil A. J. Horst · 2016 · Modern Pathology
83. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers
    Camille Buffet, Karine Perlemoine, Léopoldine Bricaire, Florent Dumont, Camille Baudry, Frédérique Tissier, Jerome Yves Bertherat, Béatrix Cochand‐Priollet, Marie‐Laure Raffin‐Sanson, Françoise Cormier et al. · 2017 · PLoS ONE
84. The multiple functions of protein phosphatase 6
    Takashi Ohama · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
85. Dysregulation of Rho GTPases in Human Cancers
    Haiyoung Jung, Suk Ran Yoon, Jeewon Lim, Hee Jun Cho, Hee Gu Lee · 2020 · Cancers
86. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
    Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng et al. · 2015 · Clinical Cancer Research
87. Recurrent inactivating mutations of ARID2 in non‐small cell lung carcinoma
    Gilles Manceau, Éric Letouzé, Cécile Guichard, Audrey Didelot, Aurélie Cazes, Hélène Corté, Elizabeth Fabre, Karine Pallier, Sandrine Imbeaud, Françoise Le Pimpec‐Barthes et al. · 2012 · International Journal of Cancer
88. Inactivating Mutations in SWI/SNF Chromatin Remodeling Genes in Human Cancer
    Takahiro Oike, Hideaki Ogiwara, Takashi Nakano, Jun Yokota, Takashi Kohno · 2013 · Japanese Journal of Clinical Oncology
89. Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma
    Joshua X. Wang, Mizuho Fukunaga‐Kalabis, Meenhard Herlyn · 2016 · Journal of Cell Communication and Signaling
90. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
    Berglind Osk Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, Henrik Jespersen, Jan Mattsson, Lisa M. Nilsson, Katarina Truvé, Marcela Dávila López, Peter L. J. Naredi, Ola Nilsson et al. · 2014 · Oncotarget
91. Current Molecular Markers of Melanoma and Treatment Targets
    Kevin Yang, Allen S. W. Oak, Radomir M. Slominski, Anna A. Brożyna, Andrzej T. Slominski · 2020 · International Journal of Molecular Sciences
92. AlternativeBRAFmutations inBRAFV600E-negative hairy cell leukaemias
    Sebastian Tschernitz, Lucia Floßbach, Margrit Bonengel, Sabine Roth, Andreas Rosenwald, Eva Geissinger · 2014 · British Journal of Haematology
93. Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral Signaling
    Peng Tan, Lian He, Jun Cui, Qian Chen, Xin Cao, Meng Lin, Qingyuan Zhu, Yinyin Li, Changsheng Xing, Xiao Hong Yu et al. · 2017 · Molecular Cell
94. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
    Ivana Yen, Frances Shanahan, Mark A. Merchant, Christine Orr, Thomas Hunsaker, Matthew R. Durk, Hank La, Xiaolin Zhang, Scott E. Martin, Eva Lin et al. · 2018 · Cancer Cell
95. Cancer Stem Cell Division: When the Rules of Asymmetry Are Broken
    Subhas Mukherjee, Jun Kong, Daniel Jay Brat · 2014 · Stem Cells and Development
96. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
    Sarah Abou Alaiwi, Amin H. Nassar, Wanling Xie, Ziad Bakouny, Jacob E. Berchuck, David A. Braun, Sylvan C. Baca, Pier Vitale Nuzzo, Ronan Flippot, Tarek H. Mouhieddine et al. · 2020 · Cancer Immunology Research
97. Activating ERBB4 mutations in non-small cell lung cancer
    Kari J. Kurppa, Konstantin A. Denessiouk, Mark S. Johnson, Klaus Elenius · 2015 · Oncogene
98. RAC 1 P29S regulates PD ‐L1 expression in melanoma
    Ha Linh Vu, Sheera R. Rosenbaum, Timothy J. Purwin, Michael A. Davies, Andrew E. Aplin · 2015 · Pigment Cell & Melanoma Research
99. The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer
    Xiaofeng Gong, Danyu Du, Yanran Deng, Yuqi Zhou, Li Sun, Shengtao Yuan · 2020 · Investigational New Drugs
100. Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage due to dysregulated Aurora-A
     Dean E. Hammond, Kang Zeng, Antonio Espert, Ricardo Nunes Bastos, Ryan D. Baron, Ulrike Grüneberg, Francis A. Barr · 2013 · Journal of Cell Science